The Genetic Epidemiology of Atopic Dermatitis
Lead Research Organisation:
University of Bristol
Department Name: Social Medicine
Abstract
Eczema is a common chronic skin disease affecting up to 30% of children and 10% of adults. The condition has a considerable impact on the lives of sufferers and their families and a significant economic burden.
Though we know eczema is influenced by genetic factors, few of the actual genes involved have been identified. This project will use a range of the most up-to-date technologies and analysis methods to identify additional genes involved in susceptibility to eczema.
Eczema can range in its severity, age-of-onset and persistence, with some sufferers also having other related 'allergic' conditions such as asthma and hayfever. Therefore, there are likely to be genes that influence very specific types of eczema and other genes that result in susceptibility to allergic conditions in general.
This project will primarily use data from the Avon Longitudinal Study of Parents and Children (ALSPAC), which recruited pregnant women in the early 1990s and has followed up the children (and parents) with regular questionnaires and clinic visits, as well as collecting DNA samples. I will combine the findings from this study with other studies of eczema genetics from around the world, to confirm our findings.
I will use questionnaire and clinic data in ALSPAC to refine how we assign people as affected eczema cases and controls (and classify the affected individuals as having different types of eczema). I will then (using a number of studies and different methods) compare the genetic information between people with and without eczema (and with different types of eczema), to estimate the extent to which all of the genetic information combined explains susceptibility to AD and identify the specific genes involved. I will also identify which molecular pathways these genes operate in to learn more about how the condition develops. I will test whether it matters whether you inherit these genetic variants from your mother or your father and test whether the effect of genes on whether you develop eczema are influenced by the environment.
The findings from this work will greatly improve our understanding of eczema and will eventually lead to better diagnoses and treatments for those affected.
Though we know eczema is influenced by genetic factors, few of the actual genes involved have been identified. This project will use a range of the most up-to-date technologies and analysis methods to identify additional genes involved in susceptibility to eczema.
Eczema can range in its severity, age-of-onset and persistence, with some sufferers also having other related 'allergic' conditions such as asthma and hayfever. Therefore, there are likely to be genes that influence very specific types of eczema and other genes that result in susceptibility to allergic conditions in general.
This project will primarily use data from the Avon Longitudinal Study of Parents and Children (ALSPAC), which recruited pregnant women in the early 1990s and has followed up the children (and parents) with regular questionnaires and clinic visits, as well as collecting DNA samples. I will combine the findings from this study with other studies of eczema genetics from around the world, to confirm our findings.
I will use questionnaire and clinic data in ALSPAC to refine how we assign people as affected eczema cases and controls (and classify the affected individuals as having different types of eczema). I will then (using a number of studies and different methods) compare the genetic information between people with and without eczema (and with different types of eczema), to estimate the extent to which all of the genetic information combined explains susceptibility to AD and identify the specific genes involved. I will also identify which molecular pathways these genes operate in to learn more about how the condition develops. I will test whether it matters whether you inherit these genetic variants from your mother or your father and test whether the effect of genes on whether you develop eczema are influenced by the environment.
The findings from this work will greatly improve our understanding of eczema and will eventually lead to better diagnoses and treatments for those affected.
Technical Summary
A comprehensive program of genetic epidemiological analysis for atopic dermatitis (AD), using state-of-the-art technologies & analytical methods.
Objectives:
1 Refine the AD phenotype definition using latent class analysis in a longitudinal epidemiological study, incorporating various data from multiple time points
2 Quantify the overall contribution made by common genetic variants to AD susceptibility & identify important pathways
3 Carry out a large-scale genome-wide association meta-analysis of improved AD definitions & subtypes
4 Refine existing signals and investigate the role of lower frequency variants in AD using next-generation sequencing
5 Investigate parent-of-origin effects using multi-generational data
6 Investigate 'gene-gene' & 'gene-environment' interactions for AD
7 Functional follow-up of AD associated variants using methylation and expression data.
Main dataset:The Avon Longitudinal Study of Parents And Children. Extensive phenotypic data has been frequently collected via clinics & questionnaires. Mothers & children have imputed genome-wide SNP data & next-generation sequencing (NGS) data will soon be available for the children. Expression and methylation data will also be available.
Additional datasets:Through existing and planned collaborations in the EAGLE consortium, I will have access to a unique resource of datasets, including TwinsUK (with NGS data), the GOYA cohort (with multi-generational data) and two family-based cohorts at QIMR.
Methods:Latent class analysis to investigate the phenotype, whole-genome methods for exploring the common genetic contribution to AD, genome-wide association analysis and meta-analysis to identify associated common variants and interactions, and collapsing techniques for identifying lower frequency variants from NGS data.
This work will increase the molecular understanding of the development of AD. This will in turn enable future treatments for AD to be designed.
Objectives:
1 Refine the AD phenotype definition using latent class analysis in a longitudinal epidemiological study, incorporating various data from multiple time points
2 Quantify the overall contribution made by common genetic variants to AD susceptibility & identify important pathways
3 Carry out a large-scale genome-wide association meta-analysis of improved AD definitions & subtypes
4 Refine existing signals and investigate the role of lower frequency variants in AD using next-generation sequencing
5 Investigate parent-of-origin effects using multi-generational data
6 Investigate 'gene-gene' & 'gene-environment' interactions for AD
7 Functional follow-up of AD associated variants using methylation and expression data.
Main dataset:The Avon Longitudinal Study of Parents And Children. Extensive phenotypic data has been frequently collected via clinics & questionnaires. Mothers & children have imputed genome-wide SNP data & next-generation sequencing (NGS) data will soon be available for the children. Expression and methylation data will also be available.
Additional datasets:Through existing and planned collaborations in the EAGLE consortium, I will have access to a unique resource of datasets, including TwinsUK (with NGS data), the GOYA cohort (with multi-generational data) and two family-based cohorts at QIMR.
Methods:Latent class analysis to investigate the phenotype, whole-genome methods for exploring the common genetic contribution to AD, genome-wide association analysis and meta-analysis to identify associated common variants and interactions, and collapsing techniques for identifying lower frequency variants from NGS data.
This work will increase the molecular understanding of the development of AD. This will in turn enable future treatments for AD to be designed.
Planned Impact
Novel pathways identified as contributing to disease could offer pharmacotherapeutic possibilities.
Beneficiaries:
Patients, clinicians, the NHS:
The increase in knowledge expected through this research is an important early step on the pathway of identifying therapeutic targets and eventually bringing a treatment to market which will impact the health of patients and have an economic impact on the NHS. Increased understanding of the molecular nature of AD will also lead to better diagnosis of the condition, which will also likely benefit the lives of AD patients and have an impact on those involved in the diagnosis and treatment of AD through the NHS.
The study participants and wider community:
By contributing to the breadth of research carried out within ALSPAC, beneficiaries will include the stake-holders of this resource (the participants and the general public). Through press releases and other engagement activities the findings from research carried out within ALSPAC are often disseminated broadly.
Full details of dissemination and engagement activities are in the 'impact to pathways' statement.
Beneficiaries:
Patients, clinicians, the NHS:
The increase in knowledge expected through this research is an important early step on the pathway of identifying therapeutic targets and eventually bringing a treatment to market which will impact the health of patients and have an economic impact on the NHS. Increased understanding of the molecular nature of AD will also lead to better diagnosis of the condition, which will also likely benefit the lives of AD patients and have an impact on those involved in the diagnosis and treatment of AD through the NHS.
The study participants and wider community:
By contributing to the breadth of research carried out within ALSPAC, beneficiaries will include the stake-holders of this resource (the participants and the general public). Through press releases and other engagement activities the findings from research carried out within ALSPAC are often disseminated broadly.
Full details of dissemination and engagement activities are in the 'impact to pathways' statement.
Organisations
- University of Bristol (Fellow, Lead Research Organisation)
- 23andMe (United States) (Collaboration)
- Karolinska Institute (Collaboration)
- Swiss Tropical & Public Health Institute (Collaboration)
- ST GEORGE'S UNIVERSITY OF LONDON (Collaboration)
- Centre for Genomic Regulation (CRG) (Collaboration)
- Kiel University (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- Helmholtz Zentrum München (Collaboration)
- University of Hasselt (Collaboration)
- Barcelona Institute for Global Health (Collaboration)
- University of San Francisco (Collaboration)
- The Statens Serum Institute (SSI) (Collaboration)
- Sanofi (Collaboration)
- Norwegian Institute of Public Health (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- University of Manchester (Collaboration)
- University of Copenhagen (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- North Carolina State University (Collaboration)
- Laboratory for Respiratory and Allergic Diseases (Collaboration)
- University of Groningen (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Norwegian Mother and Child Cohort (MoBa) (Collaboration)
- University of Western Australia (Collaboration)
- University of Dundee (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- University of Memphis (Collaboration)
- Free University of Amsterdam (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- University of Queensland (Collaboration)
- Henry Ford Health System (HFHS) (Collaboration)
- Children's Hospital of Philadelphia (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- Erasmus University Rotterdam (Collaboration)
- University Medical Center Gronigen (Collaboration)
People |
ORCID iD |
| Lavinia Paternoster (Principal Investigator / Fellow) |
Publications
Ware JJ
(2016)
Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2.
in Scientific reports
Warrington NM
(2014)
Robustness of the linear mixed effects model to error distribution assumptions and the consequences for genome-wide association studies.
in Statistical applications in genetics and molecular biology
Warrington NM
(2019)
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors.
in Nature genetics
Warrington NM
(2015)
A genome-wide association study of body mass index across early life and childhood.
in International journal of epidemiology
Warrington NM
(2018)
Maternal and fetal genetic contribution to gestational weight gain.
in International journal of obesity (2005)
Wilson-Nagrani C
(2018)
Non-syndromic Cleft Lip and Palate Polymorphisms Affect Normal Lip Morphology
in Frontiers in Genetics
Winkler TW
(2014)
Quality control and conduct of genome-wide association meta-analyses.
in Nature protocols
Zheng J
(2017)
LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis.
in Bioinformatics (Oxford, England)
| Description | AMS Springboard |
| Amount | £99,977 (GBP) |
| Funding ID | SBF003\1094 |
| Organisation | Academy of Medical Sciences (AMS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 05/2020 |
| Description | British Skin Foundation Innovative Project Award |
| Amount | £90,000 (GBP) |
| Organisation | British Skin Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Elizabeth Blackwell Institute - Proximity to Discovery Award |
| Amount | £4,683 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 08/2017 |
| Description | Innovative Medicines Initiative 2 Joint Undertaking |
| Amount | € 10,500,000 (EUR) |
| Funding ID | 821511 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 04/2019 |
| End | 03/2024 |
| Description | Postgraduate extension fellowship |
| Amount | £38,317 (GBP) |
| Organisation | University of Bristol |
| Department | Elizabeth Blackwell Institute for Health Research |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2015 |
| End | 08/2016 |
| Description | BIOMAP |
| Organisation | Sanofi |
| Country | Global |
| Sector | Private |
| PI Contribution | Provide statistical analysis expertise and post-doc time to statistical genetic and multi-omic aspects of the project |
| Collaborator Contribution | There are 31 partners - academic and industry Many roles of partners, including, clinical expertise, data access, molecular experimentation, industry routes to impact |
| Impact | TBC |
| Start Year | 2019 |
| Description | BIOMAP |
| Organisation | University of Kiel |
| Department | Department of Dermatology and Allergy |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Provide statistical analysis expertise and post-doc time to statistical genetic and multi-omic aspects of the project |
| Collaborator Contribution | There are 31 partners - academic and industry Many roles of partners, including, clinical expertise, data access, molecular experimentation, industry routes to impact |
| Impact | TBC |
| Start Year | 2019 |
| Description | EAGLE eczema |
| Organisation | 23andMe |
| Country | United States |
| Sector | Private |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Children's Hospital of Philadelphia |
| Department | Center for Applied Genomics |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Erasmus University Rotterdam |
| Department | Generation R Study |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Free University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Harvard University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Helmholtz Association of German Research Centres |
| Department | The Max Delbrück Center for Molecular Medicine (MDC) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Helmholtz Zentrum München |
| Department | Helmholtz Graduate School Environmental Health (HELENA) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Henry Ford Health System (HFHS) |
| Department | Centre for Health Policy |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Imperial College London |
| Department | School of Public Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Karolinska Institute |
| Department | Institute of Environmental Medicine |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Laboratory for Respiratory and Allergic Diseases |
| Country | Japan |
| Sector | Private |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Norwegian Institute of Public Health |
| Department | Division of Epidemiology |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | St George's University of London |
| Department | Population Health Research Institute |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | Swiss Tropical & Public Health Institute |
| Department | Department of Epidemiology and Public Health (EPH) |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | The Statens Serum Institute (SSI) |
| Country | Denmark |
| Sector | Public |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Copenhagen |
| Department | Faculty of Health and Medical Sciences |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Dundee |
| Department | College of Life Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Kiel |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Manchester |
| Department | Institute of Inflammation and Repair |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Queensland |
| Department | Genetic Epidemiology Laboratory |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of San Francisco |
| Department | School of Pharmacy and Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | EAGLE eczema |
| Organisation | University of Western Australia |
| Department | School of Women's and Infants' Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | I lead this consortium and lead the analysis team and working group. |
| Collaborator Contribution | Consortium members contribute GWAS results from their individual studies to be meta-analysed by the analysis team. Some members contribute to the analysis team and working group. |
| Impact | Paternoster et al. 2015 Nature Genetics: Atopic dermatitis GWAS paper. |
| Start Year | 2012 |
| Description | PACE eczema |
| Organisation | Barcelona Institute for Global Health |
| Country | Spain |
| Sector | Multiple |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | Erasmus University Rotterdam |
| Department | Generation R Study |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Environmental Health Sciences |
| Country | United States |
| Sector | Public |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | North Carolina State University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | Norwegian Mother and Child Cohort (MoBa) |
| Country | Norway |
| Sector | Public |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | University Medical Center Gronigen |
| Department | Rheumatology and Clinical Immunology (UMCG-R) |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | University of Hasselt |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | University of Memphis |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | PACE eczema |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I lead the PACE eczema analysis team for meta-analysis epigenome-wide association study |
| Collaborator Contribution | Provide data and analysis ideas/discussion |
| Impact | None yet |
| Start Year | 2015 |
| Description | Sara Brown |
| Organisation | University of Dundee |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have provided the majority of the statistical analysis to several collaborations on the epidemiology of atopic dermatitis |
| Collaborator Contribution | Prof Brown has provided clinical and molecular expertise |
| Impact | PMIDs: 31794059 31158401 30703100 29129583 26482879 |
| Start Year | 2012 |
| Description | Sinead Langan |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Department of Non-communicable Disease Epidemiology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provided the majority of the statistical genetic analysis in projects on the epidemiology of atopic dermatitis |
| Collaborator Contribution | Provided clinical expertise in atopic dermatitis |
| Impact | PMIDs: 31794059 31260715 |
| Start Year | 2016 |
| Description | 3rd July 2019: British Association of Dermatologists annual meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk on Gene environment interactions in atopic eczema given by post-doc Dr Ashley Budu-Aggrey |
| Year(s) Of Engagement Activity | 2019 |
| Description | article in Exchange magazine |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | I wrote an article called 'Eczema and Genetics' for the National Eczema Society's March 2016 quarterly Exchange magazine. This magazine is sent to ~3,400 members who are mostly either eczema patient's, caregivers or practitioners. The article summarised our recent eczema genetic findings and also answered some more general questions that members of the society often ask about genetics. |
| Year(s) Of Engagement Activity | 2016 |